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CLINICAL INQUIRIES
What is the evaluation and treatment
strategy for Raynaud’s phenomenon?
■ Evidence summary
Raynaud’s phenomenon is diagnosed by
a history of cold temperatures or emo-
tional stress precipitating episodic digital
artery vasospasm, according to expert
opinion. This presents as well-demarcat-
ed digital pallor and cyanosis, often fol-
lowed by reactive hyperemia occurring
15 to 20 minutes after rewarming.1,2 No
reliable office test confirms the diagnosis.
By definition, primary Raynaud’s phe-
nomenon occurs in the absence of associ-
ated diseases and is considered an exag-
gerated vasoconstrictive response to cold.
It must be distinguished from normal
mottling of the digits in response to cold
temperatures, effects of vasoconstrictive
medications, environmental injury (frost-
bite, use of vibrating tools), neuropathy,
and thoracic outlet syndrome.1,2 Experts
differ on whether laboratory evaluation
with erythrocyte sedimentation rate and
an antinuclear antibody test is necessary
for patients with primary Raynaud’s phe-
nomenon.1,3
Patients with secondary Raynaud’s
phenomenon have an underlying cause
or disease, such as scleroderma or sys-
temic lupus erythematosis.2 The finding
of distorted capillaries in the nail folds
using an ophthalmoscope set at 40+
diopter magnification is the best predic-
tor of an associated connective-tissue dis-
ease.4 A cold-water challenge to trigger
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C L I N I C A L C O M M E N T A R Y
Reserve pharmacotherapy for cases 
that are resistant to conservative measures
Raynaud’s phenomenon is one of those clinical
syndromes that stirs the desire to find an exotic
explanation, such as systemic lupus erythemato-
sus, but most often yields less glamorous results.
Usually I must tell patients that I can’t explain the
cause and recommend that they keep their hands
as warm as possible to avoid the symptoms. I
have learned to discipline myself over the years to
pursue a connective tissue cause only when other
signs or symptoms of such a disease are also pres-
ent. The use of the ophthalmoscope at high power
to look for distorted nail-fold capillary loops is a
helpful pearl.
I reserve pharmacotherapy for cases that are
resistant to conservative measures due to the cost
and side effects of the drug options. 
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Raynaud’s phenomenon is diagnosed by history,
which also plays a key role in distinguishing 
primary from secondary Raynaud’s phenomenon
(strength of recommendation [SOR]: C, based 
on expert opinion). The initial treatment includes
conservative measures such as the use of gloves,
cold avoidance, and rapid rewarming 
(SOR: C, based on expert opinion); in refractory
cases, the vasodilatory agents nifedipine or 
prazosin alleviate symptoms (SOR: A for both,
based on multiple randomized controlled 
trials) (TABLE).
E V I D E N C E - B A S E D A N S W E R
C O N T I N U E D
Medication may
be beneficial for
patients not helped
by conservative
measures—
dressing warmly,
wearing gloves,
avoiding cold and
emotional stress
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an attack of Raynaud’s phenomenon pro-
duces inconsistent results and is not rec-
ommended. Research tools such as ther-
mographic and laser Doppler imaging
can measure digital artery blood flow but
are rarely used clinically.1,5 Patients with
secondary Raynaud’s phenomenon
should have a complete blood count, bio-
chemistry profile, and urinalysis. They
may need additional tests as determined
by the nature of their underlying disease.1
Conservative management is helpful
for all patients with Raynaud’s phenome-
non, and may be the only treatment need-
ed. Experts advise dressing warmly, wear-
ing gloves when appropriate, using
abortive strategies such as placing the
hands into warm water, and avoiding sud-
den cold exposure, emotional stress, and
vasoconstrictive agents such as nicotine.6
Medication may be helpful for patients
whose symptoms are not controlled with
conservative measures. Six randomized,
placebo-controlled trials involving 451
people with primary Raynaud’s phenome-
non demonstrated that nifedipine decreases
the mean frequency of vasospastic attacks.
Three of these trials also showed subjective
improvement in symptom severity with
nifedipine vs placebo.7 A meta-analysis of 6
randomized crossover studies compared
nifedipine or nicardipine with placebo in
59 patients with secondary Raynaud’s phe-
nomenon and underlying systemic sclero-
sis. Nifedipine significantly decreased the
frequency and severity of attacks.
Nicardipine showed a trend towards
reduced symptoms in 1 trial with only 15
patients.8 Another randomized trial com-
paring sustained-release nifedipine to place-
bo showed a 66% reduction in the number
of attacks in the treatment group at 1 year;
19 of the 77 people in the nifedipine group
dropped out of the study, as did 24 of the
81 people in the placebo group.9
A systematic review of 2 randomized
controlled trials with a total of 40 patients
found prazosin modestly effective in sec-
ondary Raynaud’s phenomenon, but it
was less well-tolerated than calcium chan-
nel blockers.10 Single, small randomized
crossover trials showed improved respons-
es to both fluoxetine11 and losartan12 when
compared with nifedipine. In general,
these medications appear to reduce
attacks by 30% to 40%.
Small, prospective studies of low-
level laser irradiation, palmar sympathec-
tomy, and endoscopic thoracic sympa-
thectomy show some benefit for patients
with digital ulcers.13–15 A randomized con-
trolled trial showed biofeedback was
ineffective for voluntary control of digi-
tal blood flow for patients with
Raynaud’s phenomenon.9
Recommendations from others
The American College of Rheumatology
does not offer recommendations for the
diagnosis or treatment of Raynaud’s phe-
nomenon. UpToDate recommends treat-
ment with conservative measures; sus-
tained-release nifedipine or amlodipine
may be used if these are insufficient.
Other vasodilators may be added or sub-
stituted in the event of an adverse reac-
tion or poor response to the calcium-
channel blocker.16
T A B L E
RECOMMENDATION 
TREATMENT LEVEL COMMON ADVERSE EFFECTS
Nifedipine A Lower extremity edema, 
flushing, headache, dizziness
Prazosin A Dizziness, hypotension, palpitations
Conservative C —
Primary therapies for Raynaud’s phenomenon
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THE JOURNAL OF FAMILY PRACTICE uses a 
simplified rating system system called the
Strength of Recommendation Taxonomy
(SORT). More detailed information can 
be found in the  February 2003 issue,
“Simplifying the language of patient care,”
pages 111–120.
Strength of Recommendation (SOR) ratings
are given for key recommendations for readers.
SORs should be based on the highest-quality 
evidence available.
A Recommendation based on consistent and 
good-quality patient–oriented evidence.
B Recommendation based on inconsistent or 
limited-quality patient-oriented evidence.
C Recommendation based on consensus, usual practice,
opinion, disease-oriented evidence, or case series for 
studies of diagnosis, treatment, prevention, or screening
Levels of evidence determine whether a study
measuring patient-oriented outcomes is of
good or limited quality, and whether the results
are consistent or inconsistent between studies.
STUDY QUALITY
1—Good-quality, patient-oriented evidence 
(eg, validated clinical decision rules, systematic reviews 
and meta-analyses of randomized controlled trials
[RCTs] with consistent results, high-quality RCTs, or
diagnostic cohort studies)
2—Lower-quality patient-oriented evidence 
(eg, unvalidated clinical decision rules, lower-quality 
clinical trials, retrospective cohort studies, case control
studies, case series)
3—Other evidence (eg, consensus guidelines, usual 
practice, opinion, case series for studies of diagnosis,
treatment, prevention, or screening)
Consistency across studies 
Consistent—Most studies found similar or at least 
coherent conclusions (coherence means that differences
are explainable); or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they support
the recommendation
Inconsistent—Considerable variation among study findings
and lack of coherence; or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they do not 
find consistent evidence in favor of the recommendation
Evidence-based medicine ratings
